ETOZOLIN HYDROCHLORIDE

Details

Stereochemistry	RACEMIC
Molecular Formula	C13H20N2O3S.ClH
Molecular Weight	320.835
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CCOC(=O)\C=C1/SC(N2CCCCC2)C(=O)N1C

InChI

InChIKey=AOHAFCXGDWOODX-KVVVOXFISA-N

InChI=1S/C13H20N2O3S.ClH/c1-3-18-11(16)9-10-14(2)12(17)13(19-10)15-7-5-4-6-8-15;/h9,13H,3-8H2,1-2H3;1H/b10-9-;

HIDE SMILES / InChI

Description
Sources: http://ibdigital.uib.es/greenstone/collect/medicinaBalear/archives/Medicina/_Balear_/1993v08n/4p210.dir/Medicina_Balear_1993v08n4p210.pdf | https://www.ncbi.nlm.nih.gov/pubmed/578770

Etozolin is a diuretic used in Europe under the names Diulozin, Elkapin, Etopinil for the treatment of edema and hypertension. The exact mechanism of etozolin action is unknown. The current marketing status of the drug is unavailable and is supposed to be discontinued.

Originator

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypertension 575 Sources: https://www.ncbi.nlm.nih.gov/pubmed/578770	Primary		Approved 8583	ELKAPIN Approved Use Unknown
Edema 23 Sources: https://www.ncbi.nlm.nih.gov/pubmed/578770	Primary		Approved 8583	ELKAPIN Approved Use Unknown

F_unbound

Value	Dose	Co-administered	Analyte	Population
65% REVIEW https://link.springer.com/chapter/10.1007/978-3-642-79565-7_5 \| https://pubmed.ncbi.nlm.nih.gov/7173295/			ETOZOLIN unknown	Homo sapiens

Doses

Dose	Population	Adverse events
200 mg 1 times / day multiple, oral Studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2698939/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2698939/	Other AEs: Weakness, Epigastric pain... Other AEs: Weakness (3.9%) Epigastric pain (2.2%) Nausea (1.9%) Constipation (1.7%) Dizziness (1.4%) Headache (1.2%) Sources: https://pubmed.ncbi.nlm.nih.gov/2698939/

AEs

AE	Significance	Dose	Population
Headache	1.2%	200 mg 1 times / day multiple, oral Studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2698939/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2698939/
Dizziness	1.4%	200 mg 1 times / day multiple, oral Studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2698939/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2698939/
Constipation	1.7%	200 mg 1 times / day multiple, oral Studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2698939/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2698939/
Nausea	1.9%	200 mg 1 times / day multiple, oral Studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2698939/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2698939/
Epigastric pain	2.2%	200 mg 1 times / day multiple, oral Studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2698939/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2698939/
Weakness	3.9%	200 mg 1 times / day multiple, oral Studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2698939/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2698939/

PubMed

Title	Date	PubMed
Pharmacodynamics and kinetics of etozolin/ozolinone in hypertensive patients with normal and impaired kidney function.	1984	6386484
[Studies on the diuretic effects of etozolin (Elkapin) in heart failure - a comparison with the loop diuretic agent furosemide (author's transl)].	1979-04-20	460026
[Structure-activity relationships of etozolin, a novel diuretic (author's transl)].	1977	578762
[On the pharmacology of Etozolin (author's transl)].	1977	578763
[Toxicological studies on Etozolin (author's transl)].	1977	578765
[Effect of the diuretic Etozolin (Gö 687) on renal elimination of water and solutes in subjects with normal renal function (author's transl)].	1977	578770
Distribution of 64Cu-bleomycin in normal and tumor-bearing rats.	1976-01	57876
[LOCALIZATION OF THE SITE OF ACTION OF THE DIURETIC ETOZOLIN IN THE MEPHRON OF THE DOG AND REPORT OF A MATHEMATICAL EVALUATION METHOD OF STOP-FLOW EXPERIMENTS].	1964-11-25	14340709

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dose is 200 mg/day.

Route of Administration: Oral

In Vitro Use Guide

Isolated rings of guinea-pig aorta were treated with etozolin (10 uM-1 mM). At those concentrations, the drug inhibited noradrenaline- and histamine-induced contractions. At very low concentrations (1 nM-0.1 uM), it inhibited also serotonin-induced contractions.

Name

Type

Language

ETOZOLIN HYDROCHLORIDE

Common Name

English

.DELTA.2,.ALPHA.-THIAZOLIDINEACETIC ACID, 3-METHYL-4-OXO-5-PIPERIDINO-, ETHYL ESTER, HYDROCHLORIDE

Preferred Name

English

ETOZOLIN HYDROCHLORIDE [MI]

Common Name

English

ACETIC ACID, 2-(3-METHYL-4-OXO-5-(1-PIPERIDINYL)-2-THIAZOLIDINYLIDENE)-, ETHYL ESTER, HYDROCHLORIDE (1:1)

Systematic Name

English

ACETIC ACID, (3-METHYL-4-OXO-5-(1-PIPERIDINYL)-2-THIAZOLIDINYLIDENE)-, ETHYL ESTER, MONOHYDROCHLORIDE

Common Name

English

Code System Code Type Description

CAS

53-90-7